人类 DNA 疫苗市场 - 全球产业规模、份额、趋势、机会及预测，依给药途径、应用、最终用户、地区及竞争情况细分，2020-2030 年预测

2024 年全球人类 DNA 疫苗市场价值为 3.4544 亿美元，预计到 2030 年将达到 5.2399 亿美元，复合年增长率为 7.15%。受基因工程进步、医疗保健领域投资增加以及对尖端治疗和预防解决方案的需求增加的推动，该市场正在经历强劲增长。 DNA疫苗透过直接传递编码特定抗原的工程质粒DNA来发挥作用，刺激精确的免疫反应。这些疫苗因其增强的安全性、更短的开发时间以及对广泛疾病的适应性而脱颖而出。 DNA 疫苗市场处于充满活力的疫苗产业中，在持续的技术突破、扩大的临床应用和日益增强的全球健康优先事项的推动下，它将快速发展。符合监管趋势并在交付技术方面进行创新的公司有望获得显着的竞争优势。

关键市场驱动因素

传染病和慢性病发生率上升

主要市场挑战

有限的临床成功和监管批准

主要市场趋势

朝向基于平台的疫苗技术转变

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：顾客之声

第五章：人类DNA疫苗市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依给药途径（肌肉注射、皮下注射、皮内注射、其他）
  • 按应用（肿瘤学、结核病、爱滋病毒、其他）
  • 按最终用户（医院和诊所、生物技术和製药公司、学术和研究机构、其他）
  • 按地区
  • 按公司分类（2024）
• 市场地图

第六章：北美人类DNA疫苗市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲人类DNA疫苗市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 德国
  • 英国
  • 义大利
  • 法国
  • 西班牙

第八章：亚太人类DNA疫苗市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：南美人类DNA疫苗市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第十章：中东和非洲人类DNA疫苗市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 最新动态
• 产品发布
• 併购

第 13 章：全球人类 DNA 疫苗市场：SWOT 分析

第 14 章：竞争格局

• BOEHRINGER INGELHEIM GmbH (Merial)
• ELI-LILLY (Novartis Animal Health)
• Gene One Life Science
• GEOVAX LABS, INC
• Inovio Pharmaceuticals (VGX Animal Health)
• Genexine, Inc.
• VIATRIS INC. (Rottapharm Biotech)
• Takara Holdings (Takara Bio)
• ZOETIS INC. (Fort dodge Animal Health)
• Zydus Lifesciences Limited

第 15 章：策略建议

第16章调查会社について・免责事项

The Global Human DNA Vaccine Market was valued at USD 345.44 million in 2024 and is projected to reach USD 523.99 million by 2030, growing at a CAGR of 7.15%. This market is undergoing robust growth fueled by advancements in genetic engineering, increased investment in the healthcare sector, and heightened demand for cutting-edge therapeutic and preventive solutions. DNA vaccines operate through the direct delivery of engineered plasmid DNA encoding specific antigens, stimulating precise immune responses. These vaccines stand out for their enhanced safety profile, shorter development timelines, and adaptability across a broad spectrum of diseases. Positioned within the dynamic vaccine industry, the DNA vaccine market is poised for rapid evolution driven by continuous technological breakthroughs, expanded clinical applications, and heightened global health priorities. Companies that align with regulatory trends and innovate in delivery technologies are expected to gain significant competitive advantages.

Key Market Drivers

Rising Prevalence of Infectious and Chronic Diseases

The escalating occurrence of both infectious and chronic diseases is a critical driver for the Global Human DNA Vaccine Market. In 2021, approximately 18 million people died prematurely from noncommunicable diseases (NCDs), with 82% of these deaths occurring in low- and middle-income countries (LMICs), underscoring the disproportionate impact on economically disadvantaged regions. Furthermore, LMICs accounted for 73% of all NCD-related deaths globally. This significant health burden amplifies the need for innovative vaccination approaches like DNA vaccines, which are gaining momentum due to their unique benefits. Notably, in 2023, about 1.3 million people contracted HIV worldwide, a 39% reduction in new cases from 2010, indicating a global infection rate of 0.17 per 1,000 uninfected individuals. As diseases such as HIV, Hepatitis, Tuberculosis, HPV, COVID-19, Zika, and Ebola continue to challenge public health systems, DNA vaccines offer scalable, adaptable, and long-lasting immune protection-traits that are increasingly in demand globally.

Key Market Challenges

Limited Clinical Success and Regulatory Approvals

Despite encouraging outcomes in preclinical stages, human DNA vaccines face challenges in achieving strong clinical efficacy. A primary obstacle is their lower immunogenicity in humans when compared to traditional vaccine types, which often leads to suboptimal immune responses in clinical settings-especially when conventional administration methods are used. Consequently, regulatory approval for human use remains limited, with most authorizations to date focused on veterinary applications. Although the pandemic has accelerated interest in DNA vaccines for humans, regulatory bodies continue to require comprehensive data on long-term safety and efficacy. These stringent and often uncertain regulatory demands present a substantial hurdle, particularly for smaller biotech firms, thereby slowing commercial progress and investment in the field.

Key Market Trends

Shift Toward Platform-Based Vaccine Technologies

The vaccine sector is witnessing a strong trend toward platform-based technologies, which leverage a unified system for developing multiple vaccines. DNA vaccine platforms exemplify this model. By standardizing delivery mechanisms, production processes, and clinical trial protocols, these platforms significantly cut down on development time and costs. They also enable rapid responses to emergent health threats, supporting quicker vaccine rollouts. Pharmaceutical companies and investors are increasingly attracted to this scalable framework, which not only fosters efficient product pipelines but also strengthens pandemic preparedness strategies. These systems support diverse disease applications, enhance public-private collaborations, and draw funding from global health stakeholders.

Key Market Players

• BOEHRINGER INGELHEIM GmbH (Merial)
• ELI-LILLY (Novartis Animal Health)
• Gene One Life Science
• GEOVAX LABS, INC
• Inovio Pharmaceuticals (VGX Animal Health)
• Genexine, Inc.
• VIATRIS INC. (Rottapharm Biotech)
• Takara Holdings (Takara Bio)
• ZOETIS INC. (Fort dodge Animal Health)
• Zydus Lifesciences Limited

Report Scope:

In this report, the Global Human DNA Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Human DNA Vaccine Market, By Route of Administration:

• Intramuscular
• Subcutaneous
• Intradermal
• Others

Human DNA Vaccine Market, By Application:

• Oncology
• Tuberculosis
• HIV
• Others

Human DNA Vaccine Market, By End User:

• Hospitals & Clinics
• Biotechnology & Pharmaceutical Companies
• Academic & Research Institutions
• Others

Human DNA Vaccine Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Human DNA Vaccine Market.

Available Customizations:

Global Human DNA Vaccine market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Human DNA Vaccine Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Route of Administration (Intramuscular, Subcutaneous, Intradermal, Others)
  • 5.2.2. By Application (Oncology, Tuberculosis, HIV, Others)
  • 5.2.3. By End User (Hospitals & Clinics, Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Human DNA Vaccine Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Route of Administration
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Human DNA Vaccine Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Route of Administration
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Human DNA Vaccine Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Route of Administration
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Human DNA Vaccine Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Route of Administration
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe Human DNA Vaccine Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Route of Administration
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Human DNA Vaccine Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Route of Administration
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. United Kingdom Human DNA Vaccine Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Route of Administration
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. Italy Human DNA Vaccine Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Route of Administration
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. France Human DNA Vaccine Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Route of Administration
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Human DNA Vaccine Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Route of Administration
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia-Pacific Human DNA Vaccine Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Route of Administration
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Human DNA Vaccine Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Route of Administration
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. India Human DNA Vaccine Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Route of Administration
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Human DNA Vaccine Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Route of Administration
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Human DNA Vaccine Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Route of Administration
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Human DNA Vaccine Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Route of Administration
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. South America Human DNA Vaccine Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Route of Administration
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Human DNA Vaccine Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Route of Administration
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina Human DNA Vaccine Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Route of Administration
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia Human DNA Vaccine Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Route of Administration
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. Middle East and Africa Human DNA Vaccine Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Route of Administration
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Human DNA Vaccine Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Route of Administration
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia Human DNA Vaccine Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Route of Administration
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. UAE Human DNA Vaccine Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Route of Administration
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Human DNA Vaccine Market: SWOT Analysis

14. Competitive Landscape

• 14.1. BOEHRINGER INGELHEIM GmbH (Merial)
  • 14.1.1. Business Overview
  • 14.1.2. Product & Service Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Financials (If Listed)
  • 14.1.5. Key Personnel
  • 14.1.6. SWOT Analysis
• 14.2. ELI-LILLY (Novartis Animal Health)
• 14.3. Gene One Life Science
• 14.4. GEOVAX LABS, INC
• 14.5. Inovio Pharmaceuticals (VGX Animal Health)
• 14.6. Genexine, Inc.
• 14.7. VIATRIS INC. (Rottapharm Biotech)
• 14.8. Takara Holdings (Takara Bio)
• 14.9. ZOETIS INC. (Fort dodge Animal Health)
• 14.10.Zydus Lifesciences Limited

15. Strategic Recommendations

16. About Us & Disclaimer